These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6469556)

  • 1. Fluoride therapy in metabolic bone disease.
    Spencer H; Kramer L; Wiatrowski E; Lender M
    Isr J Med Sci; 1984 May; 20(5):373-80. PubMed ID: 6469556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between fluoride effects on bone histology and on bone mass in patients with postmenopausal osteoporosis.
    Harrison JE; Bayley TA; Josse RG; Murray TM; Sturtridge W; Williams C; Goodwin S; Tam C; Fornasier V
    Bone Miner; 1986 Sep; 1(4):321-33. PubMed ID: 3504712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LD50, excretion and serum and bone levels of F after a high single F and F + Mg dose in rats with findings on cardiac Ca and Mg.
    Koskinen-Kainulainen M; Luoma H; Tuomisto J
    Magnes Trace Elem; 1990; 9(1):15-27. PubMed ID: 2331314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate use in conditions other than osteoporosis.
    Silverman SL
    Ann N Y Acad Sci; 2011 Feb; 1218():33-7. PubMed ID: 20946575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The determination of fluoride ion concentration in biological fluids and in the serum and urine of fluoride-treated patients with Paget's disease and osteoporosis.
    Cowell DC
    Med Lab Technol; 1975 Apr; 32(2):73-89. PubMed ID: 1172180
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of aluminum hydroxide on fluoride and calcium metabolism.
    Spencer H; Kramer L; Osis D; Wiatrowski E
    J Environ Pathol Toxicol Oncol; 1985; 6(1):33-41. PubMed ID: 4067833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological availability of Ossin, a sodium-fluoride dragee for osteoporosis therapy].
    Becker R
    Fortschr Med; 1979 Jan; 97(1):39-42. PubMed ID: 759278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New viewpoints on the physiology and toxocology of fluorides].
    Hagen AR
    Nor Tannlaegeforen Tid; 1967 Oct; 77(8):469-86. PubMed ID: 5235269
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sodium fluoride in the therapy of osteoporosis].
    Krokowski E
    Fortschr Med; 1979 Oct; 97(37):1635-40. PubMed ID: 159249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
    Murray TM; Ste-Marie LG
    CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of fluoride on bone histology in postmenopausal osteoporosis depends on adequate fluoride absorption and retention.
    Budden FH; Bayley TA; Harrison JE; Josse RG; Murray TM; Sturtridge WC; Kandel R; Vieth R; Strauss AL; Goodwin S
    J Bone Miner Res; 1988 Apr; 3(2):127-32. PubMed ID: 3213607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis, osteomalacia, rickets, and Paget's disease.
    Nugent CA; Gall EP; Pitt MJ
    Prim Care; 1984 Jun; 11(2):353-68. PubMed ID: 6236469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
    Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
    Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of conventional and newer forms of treatment on calcium absorption in osteoporosis.
    Spencer H; Kramer L; Osis D; Norris C
    Isr J Med Sci; 1976 Jul; 12(7):638-51. PubMed ID: 972018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR; Minoofar PN
    Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.